- Home
- RYTM
as 03-28-2025 4:00pm EST
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 3.2B | IPO Year: | 2017 |
| Target Price: | $68.58 | AVG Volume (30 days): | 532.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.17 - $68.58 | Next Earning Date: | 05-06-2025 |
| Revenue: | $130,126,000 | Revenue Growth: | 68.06% |
| Revenue Growth (this year): | 47.06% | Revenue Growth (next year): | 68.10% |
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| German Christopher Paul | RYTM | Corporate Controller & CAO | Mar 20 '25 | Sell | $54.23 | 344 | $18,655.12 | 2,889 | |
| Mazabraud Yann | RYTM | EVP, Head of International | Mar 14 '25 | Sell | $51.26 | 75,000 | $3,861,272.37 | 96,173 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 14 '25 | Sell | $57.22 | 2,215 | $126,742.30 | 109,929 | |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Feb 14 '25 | Sell | $57.22 | 2,035 | $116,442.70 | 5,858 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 14 '25 | Sell | $57.22 | 1,228 | $70,266.16 | 8,509 | |
| Meeker David P | RYTM | President and CEO | Feb 14 '25 | Sell | $57.22 | 9,896 | $566,249.12 | 201,281 | |
| German Christopher Paul | RYTM | Corporate Controller & CAO | Feb 14 '25 | Sell | $57.22 | 635 | $36,334.70 | 2,889 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Feb 14 '25 | Sell | $57.22 | 982 | $56,190.04 | 19,209 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 12 '25 | Sell | $56.31 | 751 | $42,346.85 | 109,929 | |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Feb 12 '25 | Sell | $56.80 | 3,020 | $172,238.05 | 5,858 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Rhythm Pharmaceuticals Regains Licensing Rights to Imcivree Obesity Drug
Insider Monkey
8 days ago
Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?
GlobeNewswire
8 days ago
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
MT Newswires
9 days ago
Rhythm Gets Orphan Drug Label for Setmelanotide in Japan
GlobeNewswire
9 days ago
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
MT Newswires
10 days ago
Rhythm Pharmaceuticals Insider Sold Shares Worth $3,861,272, According to a Recent SEC Filing
GlobeNewswire
11 days ago
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
Simply Wall St.
24 days ago
US High Growth Tech Stocks to Watch in March 2025
Compare RYTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.